We are dedicated to advancing cancer research and developing new treatments by combining functional genomics and clinical genomics.

Here are our current focus areas:

Novel Regulators of Androgen Receptor (AR) Signaling

Targeting AR in Prostate Cancer: AR is the central target in prostate cancer. We utilize an endogenous AR reporter flow-based CRISPRi screen to identify novel regulators of AR signaling. This approach has led to the discovery of crucial AR regulators such as PTGES3. Our goal is to characterize these regulators in detail and explore their potential as drug targets.

Molecular Determinants of AR Independence

Understanding Lineage Transitions: We are pioneering a new approach that combines perturb-seq, CRISPRi/a screens, and multiplex-guide RNA pools to capture lineage transition events. This project aims to understand the molecular determinants underlying the transition from AR-dependent to AR-independent states.

New Immune Checkpoint and Cancer Immunotherapy Targets

Enhancing Cancer Immunotherapy: Through large cohort co-culture screens of solid tumors and immune effector cells, we identify key pathways that mediate tumor clearance. This project focuses on understanding the role of these mediators in immune evasion and developing strategies to overcome this resistance, thereby enhancing the effectiveness of cancer immunotherapy.